Advertisement

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Gail J. Roboz, Sumithra J. Mandrekar, Pinkal Desai, Kristina Laumann, Alison R. Walker, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Eyal C. Attar, Wendy Stock, Clara D. Bloomfield, Jessica Kohlschmidt, Krzysztof Mrózek, Duane C. Hassane, Levi Garraway, Judit Jané-Valbuena, Michele Baltay, Adam Tracy, Guido Marcucci, Richard M. Stone and Richard A. Larson

Article Information

Citation 
vol. 2 no. 24 3608-3617
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted July 16, 2018
  • Accepted October 13, 2018
  • Published online December 19, 2018.


Contributors 
  • Gail J. Roboz, 1Division of Hematology and Oncology, Department of Medicine, Weill Medical College, Cornell University, New York, NY;2New York Presbyterian Hospital, New York, NY;
  • Sumithra J. Mandrekar, 3Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;
  • Pinkal Desai, 1Division of Hematology and Oncology, Department of Medicine, Weill Medical College, Cornell University, New York, NY;2New York Presbyterian Hospital, New York, NY;
  • Kristina Laumann, 3Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;
  • Alison R. Walker, 4The Ohio State University Comprehensive Cancer Center, Columbus, OH;
  • Eunice S. Wang, 5Roswell Park Comprehensive Cancer Center, Buffalo, NY;
  • Jonathan E. Kolitz, 6Monter Cancer Center, Northwell Health System, Lake Success, NY;7Division of Hematology Oncology, Department of Medicine, Zucker School of Medicine, Hofstra Northwell, Lake Success, NY;
  • Bayard L. Powell, 8Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC;
  • Eyal C. Attar, 9Massachusetts General Hospital, Boston, MA;
  • Wendy Stock, 10University of Chicago Comprehensive Cancer Center, Chicago, IL;
  • Clara D. Bloomfield, 4The Ohio State University Comprehensive Cancer Center, Columbus, OH;
  • Jessica Kohlschmidt, 3Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;4The Ohio State University Comprehensive Cancer Center, Columbus, OH;
  • Krzysztof Mrózek, 4The Ohio State University Comprehensive Cancer Center, Columbus, OH;
  • Duane C. Hassane, 1Division of Hematology and Oncology, Department of Medicine, Weill Medical College, Cornell University, New York, NY;2New York Presbyterian Hospital, New York, NY;
  • Levi Garraway, 11Dana-Farber/Partners CancerCare, Boston, MA;12Center for Cancer Precision Medicine, Department of Medicine, Harvard Medical School, Boston, MA;13Broad Institute of Harvard and MIT, Cambridge, MA;
  • Judit Jané-Valbuena, 13Broad Institute of Harvard and MIT, Cambridge, MA;
  • Michele Baltay, 14Brigham and Women’s Hospital, Boston, MA; and
  • Adam Tracy, 13Broad Institute of Harvard and MIT, Cambridge, MA;
  • Guido Marcucci, 15City of Hope Comprehensive Cancer Center, Duarte, CA
  • Richard M. Stone, 11Dana-Farber/Partners CancerCare, Boston, MA;
  • Richard A. Larson, 10University of Chicago Comprehensive Cancer Center, Chicago, IL;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output